GcMAF Immune Therapy
A precision-engineered macrophage activating protein available in two clinical-grade formulations — manufactured to GMP standards and independently verified for potency, sterility, and biological activity.
Choose Your Formulation
Both formulations contain identical active content — the choice depends on your clinic's storage infrastructure and distribution requirements.
GcMAF Liquid
Ready-to-Use Injectable Solution
Our liquid formulation offers immediate bioavailability with no reconstitution required. Delivered as a ready-to-use injectable, it is optimised for clinical environments with consistent refrigeration infrastructure.
- Immediate absorption and bioavailability
- Flexible clinical dosing protocols
- Ready to administer upon receipt
- Ideal for regular administration schedules
GcMAF Lyophilized
Freeze-Dried Powder Formulation
Our lyophilized (freeze-dried) formulation maintains full potency without refrigeration, making it the preferred choice for international distribution, long-term stockpiling, and clinics in regions with limited cold-chain infrastructure.
- Simplified global shipping logistics
- Long-term stockpiling capability
- No special cold storage required
- Full potency preserved post-reconstitution
Key Product Features
Every batch of Immunax-GcMAF products undergoes rigorous quality control to ensure consistent potency, safety, and clinical-grade standards.
ISO/GMP Certified Manufacturing
Produced in ISO-certified, GMP-compliant facilities with full quality documentation.
Third-Party Sterility Tested
Each batch independently tested for sterility, endotoxins, and microbial contamination.
Transcriptomic Activity Verified
Biological activity confirmed via transcriptomic assays on human macrophage cell lines.
Exceeds LPS Activation Standard
Macrophage activation potential exceeds the lipopolysaccharide (LPS) benchmark standard.
Prescription-Only Medical Grade
Distributed exclusively to licensed physicians and accredited medical institutions.
10+ Years Production Experience
Over a decade of uninterrupted clinical-grade GcMAF production and distribution.
Reported Beneficial Effects
The following potential benefits have been described in peer-reviewed publications. All effects are reported as “may help” or “has been shown to” — individual results vary and are subject to clinical supervision.
Mechanism of Action
Understanding how GcMAF works at a cellular level helps explain its broad applicability across immune-compromised disease states.
Nagalase Suppression in Disease
In cancer, viral infection, and neurological disease, nagalase — an enzyme secreted by pathogens and tumour cells — deglycosylates GcProtein, preventing the endogenous production of GcMAF. Macrophage activity is effectively disabled.
Exogenous GcMAF Administration
Pharmaceutical-grade GcMAF is administered via injection, bypassing the nagalase blockade. The active GcMAF protein enters circulation and encounters macrophage surface receptors.
Receptor Binding & Activation
GcMAF binds to specific receptors (including Gc-globulin receptors) on macrophage surfaces, triggering intracellular signalling cascades that activate the cell's phagocytic and cytotoxic functions.
Immune Cascade Initiation
Activated macrophages release cytokines that communicate with T-lymphocytes, NK cells, and dendritic cells — orchestrating a broad, coordinated immune response against the identified threat.
Safety Information
Immunax-GcMAF products are manufactured to GMP standards and independently verified. The following safety profile is based on published scientific literature.
Bioidentical Origin
GcMAF is a naturally-occurring protein found in healthy human serum and in mother's breast milk (colostrum). It is not a synthetic molecule — it is a bioidentical form of an endogenous immune factor.
Zero Reported Adverse Events
Over 30 years of peer-reviewed clinical literature report no serious adverse events attributable to GcMAF at therapeutic doses. This safety record is among the most robust of any immunotherapy agent.
Minor Detox Symptoms Possible
At higher doses, some patients may experience mild, temporary flu-like symptoms (fatigue, low-grade fever, mild aching) consistent with heightened immune activation. These are self-limiting and typically resolve within 24–72 hours.
GMP Compliance: All Immunax-GcMAF products are manufactured in ISO-certified, GMP-compliant facilities with full quality documentation, third-party sterility testing, and transcriptomic activity verification on human macrophage cell lines.
Ingredients
Immunax-GcMAF formulations contain two key protein components at precisely controlled concentrations, verified by third-party analytical testing.
GcMAF
Active Ingredient
400ng
per dose
The primary macrophage activating factor. Binds directly to macrophage receptors to initiate immune activation cascade.
GcProtein
Precursor
2000ng
per dose
Vitamin D Binding Protein — the natural precursor from which GcMAF is enzymatically derived. Required for biosynthesis and co-administration.
Frequently Asked Questions
Common questions from physicians and clinic administrators about GcMAF therapy.
Prescription-Only Notice
GcMAF is a prescription-only product. We distribute exclusively to licensed physicians and accredited medical clinics. For patient access, please consult a qualified healthcare professional. Immunax-GcMAF does not supply directly to individual patients under any circumstances.
If you are a physician or clinic administrator interested in procurement, please contact our medical distribution team.
Contact Our Distribution Team